Targeting multidrug resistance in cancer
By G. Szakács, Jill K. Paterson, J. Ludwig, Catherine L. Booth-Genthe, Michael M. Gottesman. Nature reviews. Drug discovery, 2006
3,544 citations recorded by the source corpus.
Subfields: Infectious Diseases, Molecular Biology, Oncology
View Paper: https://www.semanticscholar.org/paper/a779d95593f064ce5568295467a037c4c638a2ca
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Infectious Diseases
In Molecular Biology
- Subash C. Gupta
- Bharat B. Aggarwal
- Eric C. Holland
- A. Kabanov
- M. Chaturvedi
- Simone Reuter
- E. Batrakova
- Jason T. Huse
In Oncology
- Subash C. Gupta
- Bharat B. Aggarwal
- Eric C. Holland
- Zhesheng Chen
- Simone Reuter
- G. Barrera
- F. Sharom
- P. Dirks
Citations in the corpus
- Oxidative Stress and Lipid Peroxidation Products in Cancer Progression and Therapy (2012, background): “…without killing normal cell represents a new therapeutic strategy even if a more detailed understanding of ROS-mediated signaling in tumor cells and in tumor stem cells is necessary to develop the therapeutic intervention to selectively kill cancer cells and overcome drug and radiation resistance.”
- Autophagy and chemotherapy resistance: a promising therapeutic target for cancer treatment (2013, background): “mechanisms including tumor cell heterogeneity, drug efflux and metabolism and tumor microenvironment stress-induced genetic or epigenetic alterations as a cellular response to drug exposure (Figure 1).(1,2) Among these mechanisms, the”
- Tumour-initiating cells: challenges and opportunities for anticancer drug discovery (2009, background): “Although ABC transporter activity can result in tumour-initiating cells being relatively resistant to many conventional therapies, it may make the cells susceptible to alternative strategies that target cells with effective drug efflu”
- ABC multidrug transporters: structure, function and role in chemoresistance. (2008, background): “trials of Pgp modulation in cancer, which have so far been disappointing [73].”
- Engineered Design of Mesoporous Silica Nanoparticles to Deliver Doxorubicin and Pgp siRNA to Overcome Drug Resistance in a Cancer Cell Line (2010, neutral): “ach, breast, pancreas, and cervix in response to a number of chemotherapeutics agents.(8)”